报价延迟最少15分钟:2026/07/04 10:31 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
19.83 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.84/1.22
|
|
企业价值
44.29B
|
| 资产负债 |
|
每股账面净值
5.53
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
15.12B
|
|
每股收益
8.03
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, includingTylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026. |
